Melbourne, Nov 17, 2008 (ABN Newswire) - Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that the multiple centres involved in the Phase III clinical trail on its long acting neuraminidase inhibitor (LANI) CS-8958 are ready to commence treatment. Patients are expected to enrol into the study progressively throughout the Asian influenza season.
